Media stories about Anavex Life Sciences Corp. (NASDAQ:AVXL) have been trending somewhat positive on Sunday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anavex Life Sciences Corp. earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.6029956096269 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Anavex Life Sciences Corp. (NASDAQ AVXL) traded down $0.02 during trading on Friday, hitting $4.08. The stock had a trading volume of 111,937 shares, compared to its average volume of 352,503. Anavex Life Sciences Corp. has a 12-month low of $3.17 and a 12-month high of $6.64.

AVXL has been the subject of a number of recent research reports. ValuEngine upgraded Anavex Life Sciences Corp. from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. Maxim Group set a $15.00 target price on Anavex Life Sciences Corp. and gave the stock a “buy” rating in a report on Monday, August 7th. Noble Financial reiterated a “buy” rating on shares of Anavex Life Sciences Corp. in a report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a report on Thursday, August 10th.

COPYRIGHT VIOLATION WARNING: “Anavex Life Sciences Corp. (AVXL) Earns News Sentiment Rating of 0.25” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Insider Buying and Selling by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with's FREE daily email newsletter.